Long-term safety of drug-eluting stents

References

• Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1(8058), 263 (1978).
   PubMed Web of Science ®Google Scholar
• de Feyter PJ, de Jaegere PP, Serruys PW. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am. Heart J. 127(3), 643–651 (1994).
   PubMed Web of Science ®Google Scholar
• Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 86(6 Suppl.), III47–52 (1992).
   PubMed Web of Science ®Google Scholar
• Gruentzig AR, King SB3rd, Schlumpf M, Siegenthaler W. Long-term follow-up after percutaneous transluminal coronary angioplasty. The early Zurich experience. N. Engl. J. Med. 316(18), 1127–1132 (1987).
   PubMed Web of Science ®Google Scholar
• Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N. Engl. J. Med. 316(12), 701–706 (1987).
   PubMed Web of Science ®Google Scholar
• Roubin GS, Robinson KA, King SB3rd et al. Early and late results of intracoronary arterial stenting after coronary angioplasty in dogs. Circulation 76(4), 891–897 (1987).
   PubMed Web of Science ®Google Scholar
• Serruys PW, de Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent study group. N. Engl. J. Med. 331(8), 489–495 (1994).
   PubMed Web of Science ®Google Scholar
• Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N. Engl. J. Med. 331(8), 496–501 (1994).
   PubMed Web of Science ®Google Scholar
• Colombo A, Hall P, Nakamura S et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 91(6), 1676–1688 (1995).
   PubMed Web of Science ®Google Scholar
• Schomig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med. 334(17), 1084–1089 (1996).
   PubMed Web of Science ®Google Scholar
• Sangiorgi G, Melzi G, Agostoni P et al. Engineering aspects of stents design and their translation into clinical practice. Ann. Ist Super. Sanita. 43(1), 89–100 (2007).
   PubMedGoogle Scholar
• Haude M, Erbel R, Straub U, Dietz U, Meyer J. Short and long term results after intracoronary stenting in human coronary arteries: monocentre experience with the balloon-expandable Palmaz-Schatz stent. Br. Heart J. 66(5), 337–345 (1991).
   PubMedGoogle Scholar
• Lossef SV, Lutz RJ, Mundorf J, Barth KH. Comparison of mechanical deformation properties of metallic stents with use of stress-strain analysis. J. Vasc. Interv. Radiol. 5(2), 341–349 (1994).
   PubMed Web of Science ®Google Scholar
• Rogers C, Edelman ER. Endovascular stent design dictates experimental restenosis and thrombosis. Circulation 91(12), 2995–3001 (1995).
   PubMed Web of Science ®Google Scholar
• Kastrati A, Mehilli J, Dirschinger J et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 103(23), 2816–2821 (2001).
   PubMed Web of Science ®Google Scholar
• Pache J, Kastrati A, Mehilli J et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR–STEREO-2) trial. J. Am. Coll. Cardiol. 41(8), 1283–1288 (2003).
   PubMed Web of Science ®Google Scholar
• Kwok OH. Stent “concertina:” stent design does matter. J. Invasive. Cardiol. 25(6), E114–E119 (2013).
   PubMed Web of Science ®Google Scholar
• Leibundgut G, Gick M, Toma A et al. Longitudinal compression of the platinum-chromium everolimus-eluting stent during coronary implantation: predisposing mechanical properties, incidence, and predictors in a large patient cohort. Catheter. Cardiovasc. Interv. 81(5), E206–E214 (2013).
   Web of Science ®Google Scholar
• Papafaklis MI, Chatzizisis YS, Naka KK, Giannoglou GD, Michalis LK. Drug-eluting stent restenosis: effect of drug type, release kinetics, hemodynamics and coating strategy. Pharmacol. Ther. 134(1), 43–53 (2012).
   PubMed Web of Science ®Google Scholar
• Nebeker JR, Virmani R, Bennett CL et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J. Am. Coll. Cardiol. 47(1), 175–181 (2006).
   PubMed Web of Science ®Google Scholar
• Nakazawa G, Ladich E, Finn AV, Virmani R. Pathophysiology of vascular healing and stent mediated arterial injury. EuroIntervention 4( Suppl C), C7–10 (2008).
   Google Scholar
• Byrne RA, Kastrati A, Massberg S et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. J. Am. Coll. Cardiol. 58(13), 1325–1331 (2011).
   PubMed Web of Science ®Google Scholar
• Stefanini GG, Kalesan B, Serruys PW et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 378(9807), 1940–1948 (2011).
   PubMed Web of Science ®Google Scholar
• King L, Byrne RA, Mehilli J, Schomig A, Kastrati A, Pache J. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial. Catheter. Cardiovasc. Interv. 81(1), E23–E28 (2013).
   PubMed Web of Science ®Google Scholar
• Braun-Dullaeus RC, Mann MJ, Seay U et al. Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin. Arterioscler. Thromb. Vasc. Biol. 21(7), 1152–1158 (2001).
   PubMed Web of Science ®Google Scholar
• Herrmann HC, Buchbinder M, Clemen MW et al. Emergent use of balloon-expandable coronary artery stenting for failed percutaneous transluminal coronary angioplasty. Circulation 86(3), 812–819 (1992).
   PubMed Web of Science ®Google Scholar
• Savage MP, Fischman DL, Schatz RA et al. Long-term angiographic and clinical outcome after implantation of a balloon-expandable stent in the native coronary circulation. Palmaz-Schatz stent study group. J. Am. Coll. Cardiol. 24(5), 1207–1212 (1994).
   PubMed Web of Science ®Google Scholar
• Kiemeneij F, Serruys PW, Macaya C et al. Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trial. J. Am. Coll. Cardiol. 37(6), 1598–1603 (2001).
   PubMed Web of Science ®Google Scholar
• Oliver LN, Buttner PG, Hobson H, Golledge J. A meta-analysis of randomised controlled trials assessing drug-eluting stents and vascular brachytherapy in the treatment of coronary artery in-stent restenosis. Int. J. Cardiol. 126(2), 216–223 (2008).
   PubMed Web of Science ®Google Scholar
• Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346(23), 1773–1780 (2002).
   PubMed Web of Science ®Google Scholar
• Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349(14), 1315–1323 (2003).
   PubMed Web of Science ®Google Scholar
• Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 350(3), 221–231 (2004).
   PubMed Web of Science ®Google Scholar
• Schofer J, Schluter M, Gershlick AH et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362(9390), 1093–1099 (2003).
   PubMed Web of Science ®Google Scholar
• Ardissino D, Cavallini C, Bramucci E et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 292(22), 2727–2734 (2004).
   PubMed Web of Science ®Google Scholar
• Grube E, Silber S, Hauptmann KE et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107(1), 38–42 (2003).
   PubMed Web of Science ®Google Scholar
• Colombo A, Drzewiecki J, Banning A et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108(7), 788–794 (2003).
   PubMed Web of Science ®Google Scholar
• Park SJ, Shim WH, Ho DS et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N. Engl. J. Med. 348(16), 1537–1545 (2003).
   PubMed Web of Science ®Google Scholar
• Gershlick A, De Scheerder I, Chevalier B et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 109(4), 487–493 (2004).
   PubMed Web of Science ®Google Scholar
• Stone GW, Parise H, Witzenbichler B et al. Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. J. Am. Coll. Cardiol. 56(19), 1597–1604 (2010).
   PubMed Web of Science ®Google Scholar
• Windecker S, Mayer I, De Pasquale G et al. Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia. Circulation 104(8), 928–933 (2001).
   PubMed Web of Science ®Google Scholar
• Angioi M, Barragan P, Cattan S et al. French Ministry of Health prospective multicentre study using bio-active stents coated with titanium nitride oxide: the EVIDENCE registry. Arch. Cardiovasc. Dis. 105(2), 60–67 (2012).
   PubMed Web of Science ®Google Scholar
• Pilgrim T, Raber L, Limacher A et al. Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial. JACC Cardiovasc. Interv. 4(6), 672-682 (2011).
   Web of Science ®Google Scholar
• Liistro F, Colombo A. Late acute thrombosis after paclitaxel eluting stent implantation. Heart 86(3), 262–264 (2001).
   PubMed Web of Science ®Google Scholar
• Waksman R, Bhargava B, Mintz GS et al. Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. J. Am. Coll. Cardiol. 36(1), 65–68 (2000).
   PubMed Web of Science ®Google Scholar
• Maehara A, Mintz GS, Weissman NJ et al. Late thrombosis after gamma-brachytherapy. Catheter. Cardiovasc. Interv. 58(4), 455–458 (2003).
   PubMed Web of Science ®Google Scholar
• Sheppard R, Eisenberg MJ, Donath D, Meerkin D. Intracoronary brachytherapy for the prevention of restenosis after percutaneous coronary revascularization. Am. Heart J. 146(5), 775–786 (2003).
   PubMed Web of Science ®Google Scholar
• Martin DM, Boyle FJ. Drug-eluting stents for coronary artery disease: a review. Med. Eng. Phys. 33(2), 148–163 (2011).
   PubMed Web of Science ®Google Scholar
• Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am. J. Med. 119(12), 1056–1061 (2006).
   PubMed Web of Science ®Google Scholar
• Stone GW, Moses JW, Ellis SG et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N. Engl. J. Med. 356(10), 998–1008 (2007).
   PubMed Web of Science ®Google Scholar
• Kastrati A, Mehilli J, Pache J et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N. Engl. J. Med. 356(10), 1030–1039 (2007).
   PubMed Web of Science ®Google Scholar
• Pfisterer M, Brunner-La Rocca HP, Buser PT et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol. 48(12), 2584–2591 (2006).
   PubMed Web of Science ®Google Scholar
• Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N. Engl. J. Med. 356(10), 1009–1019 (2007).
   PubMed Web of Science ®Google Scholar
• Stolker JM, Cohen DJ, Lindsey JB, Kennedy KF, Kleiman NS, Marso SP. Mode of death after contemporary percutaneous coronary intervention: a report from the Evaluation of drug eluting stents and ischemic events registry. Am. Heart J. 162(5), 914–921 (2011).
   PubMed Web of Science ®Google Scholar
• Shishehbor MH, Goel SS, Kapadia SR et al. Long-term impact of drug-eluting stents versus bare-metal stents on all-cause mortality. J. Am. Coll. Cardiol. 52(13), 1041–1048 (2008).
   PubMed Web of Science ®Google Scholar
• Wilson WM, Andrianopoulos N, Clark D et al. Long-term predictors of mortality after percutaneous coronary intervention in the era of drug-eluting stents. Am. J. Cardiol. 108(7), 936–942 (2011).
   PubMed Web of Science ®Google Scholar
• Kukreja N, Onuma Y, Garcia-Garcia H et al. Three-year clinical event rates in different age groups after contemporary percutaneous coronary intervention. EuroIntervention. 7(8), 969–976 (2011).
   PubMed Web of Science ®Google Scholar
• Simsek C, Magro M, Boersma E et al. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries. JACC Cardiovasc. Interv. 3(10), 1051–1058 (2010).
   PubMed Web of Science ®Google Scholar
• Windecker S, Meier B. Late coronary stent thrombosis. Circulation 116(17), 1952–1965 (2007).
   PubMed Web of Science ®Google Scholar
• Cutlip DE, Windecker S, Mehran R et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115(17), 2344–2351 (2007).
   PubMed Web of Science ®Google Scholar
• Kimura T, Abe K, Shizuta S et al. Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries. Circulation 105(25), 2986–2991 (2002).
   PubMed Web of Science ®Google Scholar
• Pfisterer ME, Jeger R, Kaiser CA. Limited usefulness of the modified Academic Research Consortium stent thrombosis definition for clinical trials. JACC Cardiovasc. Interv. 4(10), 1151, author reply 1151–1152 (2011).
   Google Scholar
• Wang F, Stouffer GA, Waxman S, Uretsky BF. Late coronary stent thrombosis: early vs. late stent thrombosis in the stent era. Catheter. Cardiovasc. Interv. 55(2), 142–147 (2002).
   PubMed Web of Science ®Google Scholar
• Wenaweser P, Rey C, Eberli FR et al. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur. Heart J. 26(12), 1180–1187 (2005).
   PubMed Web of Science ®Google Scholar
• Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293(17), 2126–2130 (2005).
   PubMed Web of Science ®Google Scholar
• Stettler C, Wandel S, Allemann S et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370(9591), 937–948 (2007).
   PubMed Web of Science ®Google Scholar
• Caixeta A, Leon MB, Lansky AJ et al. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. J. Am. Coll. Cardiol. 54(10), 894–902 (2009).
   PubMed Web of Science ®Google Scholar
• Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N. Engl. J. Med. 356(10), 989–997 (2007).
   PubMed Web of Science ®Google Scholar
• Wenaweser P, Daemen J, Zwahlen M et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J. Am. Coll. Cardiol. 52(14), 1134–1140 (2008).
   PubMed Web of Science ®Google Scholar
• D'Ascenzo F, Bollati M, Clementi F et al. Incidence and predictors of coronary stent thrombosis: Evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int. J. Cardiol. 167(2), 575–584 (2012).
   PubMed Web of Science ®Google Scholar
• van Werkum JW, Heestermans AA, Zomer AC et al. Predictors of coronary stent thrombosis: the Dutch stent thrombosis registry. J. Am. Coll. Cardiol. 53(16), 1399–1409 (2009).
   PubMed Web of Science ®Google Scholar
• Kimura T, Morimoto T, Nakagawa Y et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation 125(4), 584–591 (2012).
   PubMed Web of Science ®Google Scholar
• van Werkum JW, Heestermans AA, de Korte FI et al. Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases. Circulation 119(6), 828–834 (2009).
   PubMed Web of Science ®Google Scholar
• Holmes DRJr, Kereiakes DJ, Garg S et al. Stent thrombosis. J. Am. Coll. Cardiol. 56(17), 1357–1365 (2010).
   PubMed Web of Science ®Google Scholar
• Guagliumi G, Farb A, Musumeci G et al. Images in cardiovascular medicine. Sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings. Circulation 107(9), 1340–1341 (2003).
   PubMed Web of Science ®Google Scholar
• Finn AV, Joner M, Nakazawa G et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115(18), 2435–2441 (2007).
   PubMed Web of Science ®Google Scholar
• Nakazawa G, Finn AV, Vorpahl M, Ladich ER, Kolodgie FD, Virmani R. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. J. Am. Coll. Cardiol. 57(4), 390–398 (2011).
   PubMed Web of Science ®Google Scholar
• Nakazawa G, Finn AV, Joner M et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation 118(11), 1138–1145 (2008).
   PubMed Web of Science ®Google Scholar
• Virmani R, Guagliumi G, Farb A et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109(6), 701–705 (2004).
   PubMed Web of Science ®Google Scholar
• Cook S, Ladich E, Nakazawa G et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 120, 391–399 (2009).
   PubMed Web of Science ®Google Scholar
• Luscher TF, Steffel J, Eberli FR et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115(8), 1051–1058 (2007).
   PubMed Web of Science ®Google Scholar
• Nakazawa G. Stent thrombosis of drug eluting stent: pathological perspective. J. Cardiol. 58(2), 84–91 (2011).
   PubMed Web of Science ®Google Scholar
• Pinto Slottow TL, Waksman R. Overview of the 2006 Food and drug administration circulatory system devices panel meeting on drug-eluting stent thrombosis. Catheter. Cardiovasc. Interv. 69(7), 1064–1074 (2007).
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter. Cardiovasc. Interv. 79(3), 453–495 (2012).
   PubMed Web of Science ®Google Scholar
• Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial revascularization. Eur. Heart J. 31(20), 2501–2555 (2010).
   PubMed Web of Science ®Google Scholar
• Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369(9562), 667–678 (2007).
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Campo G, Monti M et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 125(16), 2015–2026 (2012).
   PubMed Web of Science ®Google Scholar
• Gwon HC, Hahn JY, Park KW et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 125(3), 505–513 (2012).
   PubMed Web of Science ®Google Scholar
• Eisenstein EL, Anstrom KJ, Kong DF et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297(2), 159–168 (2007).
   PubMed Web of Science ®Google Scholar
• Pfisterer M, Kaiser C, Jeger R. No one-size-fits-all: a tailored approach to antithrombotic therapy after stent. Circulation 125(3), 471–473 (2012).
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001–2015 (2007).
   PubMed Web of Science ®Google Scholar
• Mahoney EM, Wang K, Arnold SV et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation 121(1), 71–79 (2010).
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045–1057 (2009).
   PubMed Web of Science ®Google Scholar
• Stone GW, Maehara A, Lansky AJ et al. A prospective natural-history study of coronary atherosclerosis. N. Engl. J. Med. 364(3), 226–235 (2011).
   PubMed Web of Science ®Google Scholar
• Zellweger MJ, Kaiser C, Jeger R et al. Coronary artery disease progression late after successful stent implantation. J. Am. Coll. Cardiol. 59(9), 793–799 (2012).
   PubMed Web of Science ®Google Scholar
• Saia F, Sianos G, Hoye A et al. Long-term outcome of percutaneous coronary interventions following failed beta-brachytherapy. J. Invasive. Cardiol. 16(2), 60–64 (2004).
   PubMedGoogle Scholar
• Kastrati A, Elezi S, Dirschinger J, Hadamitzky M, Neumann FJ, Schomig A. Influence of lesion length on restenosis after coronary stent placement. Am. J. Cardiol. 83(12), 1617–1622 (1999).
   PubMed Web of Science ®Google Scholar
• Kastrati A, Dibra A, Mehilli J et al. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 113(19), 229–300 (2006).
   Web of Science ®Google Scholar
• Park DW, Park SW, Park KH et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am. J. Cardiol. 98(3), 352–356 (2006).
   PubMed Web of Science ®Google Scholar
• Claessen BE, Smits PC, Kereiakes DJ et al. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (clinical evaluation of the XIENCE V everolimus eluting coronary stent system) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) randomized trials. JACC Cardiovasc. Interv. 4(11), 1209–1215 (2011).
   PubMed Web of Science ®Google Scholar
• Hsieh IC, Chien CC, Chang HJ et al. Acute and long-term outcomes of stenting in coronary vessel > 3.0 mm, 3.0–2.5 mm, and < 2.5 mm. Catheter. Cardiovasc. Interv. 53(3), 314–322 (2001).
   PubMed Web of Science ®Google Scholar
• Brunner-La Rocca HP, Kaiser C, Pfisterer M. Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET). Eur. Heart J. 28(6), 719–725 (2007).
   PubMed Web of Science ®Google Scholar
• Pfisterer M, Brunner-La Rocca HP, Rickenbacher P et al. Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. Eur. Heart J. 30(1), 16–24 (2009).
   PubMed Web of Science ®Google Scholar
• Yan BP, Ajani AE, New G et al. Are drug-eluting stents indicated in large coronary arteries? Insights from a multi-centre percutaneous coronary intervention registry. Int. J. Cardiol. 130(3), 374–379 (2008).
   PubMed Web of Science ®Google Scholar
• Cortese B, Bertoletti A, De Matteis S, Danzi GB, Kastrati A. Drug-eluting stents perform better than bare metal stents in small coronary vessels: a meta-analysis of randomised and observational clinical studies with mid-term follow up. Int. J. Cardiol. 161(2), 73–82 (2012).
   PubMed Web of Science ®Google Scholar
• Puymirat E, Mangiacapra F, Peace A et al. Long-term clinical outcome in patients with small vessel disease treated with drug-eluting versus bare-metal stenting. Am. Heart. J. 162(5), 907–913 (2011).
   PubMed Web of Science ®Google Scholar
• Ito H, Hermiller JB, Yaqub M et al. Performance of everolimus-eluting versus paclitaxel-eluting coronary stents in small vessels: results from the SPIRIT III and SPIRIT IV clinical trials. J. Interv. Cardiol. 24(6), 505–513 (2011).
   PubMed Web of Science ®Google Scholar
• Braun B. Basket-small 2: first patient enrolled in landmark clinical trial. PCRonline. 12th April (2012).
   Google Scholar
• Kozuma K, Costa MA, Sabate M et al. Late stent malapposition occurring after intracoronary beta-irradiation detected by intravascular ultrasound. J. Invasive. Cardiol. 11(10), 651–655 (1999).
   PubMed Web of Science ®Google Scholar
• Schinkel AF, Barlis P, van Beusekom HM, Serruys PW, Regar E. Images in intervention. Optical coherence tomography findings in very late ST. JACC Cardiovasc. Interv. 1(4), 449–451 (2008).
   PubMed Web of Science ®Google Scholar
• Mintz GS, Weissman NJ, Fitzgerald PJ. Intravascular ultrasound assessment of the mechanisms and results of brachytherapy. Circulation 104(11), 1320–1325 (2001).
   PubMed Web of Science ®Google Scholar
• Waksman R, Bhargava B, Leon MB. Late thrombosis following intracoronary brachytherapy. Catheter. Cardiovasc. Interv. 49(3), 344–347 (2000).
   PubMed Web of Science ®Google Scholar
• Hong MK, Mintz GS, Lee CW et al. Incidence, mechanism, predictors, and long-term prognosis of late stent malapposition after bare-metal stent implantation. Circulation 109(7), 881–886 (2004).
   PubMed Web of Science ®Google Scholar
• Ako J, Morino Y, Honda Y et al. Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis. J. Am. Coll. Cardiol. 46(6), 1002–1005 (2005).
   PubMed Web of Science ®Google Scholar
• Cook S, Wenaweser P, Togni M et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 115(18), 2426–2434 (2007).
   PubMed Web of Science ®Google Scholar
• Shah VM, Mintz GS, Apple S, Weissman NJ. Background incidence of late malapposition after bare-metal stent implantation. Circulation 106(14), 175–755 (2002).
   Web of Science ®Google Scholar
• Hong MK, Mintz GS, Lee CW et al. Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation 113(3), 414–419 (2006).
   PubMed Web of Science ®Google Scholar
• Guagliumi G, Costa MA, Sirbu V et al. Strut coverage and late malapposition with paclitaxel-eluting stents compared with bare metal stents in acute myocardial infarction: optical coherence tomography substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. Circulation 123(3), 274–281 (2011).
   PubMed Web of Science ®Google Scholar
• Cook S, Eshtehardi P, Kalesan B et al. Impact of incomplete stent apposition on long-term clinical outcome after drug-eluting stent implantation. Eur. Heart J. 33(11), 1334–1343 (2012).
   PubMed Web of Science ®Google Scholar
• Hassan AK, Bergheanu SC, Stijnen T et al. Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur. Heart J. 31(10), 1172–1180 (2010).
   PubMed Web of Science ®Google Scholar
• Feres F, Costa JR, Jr., Abizaid A. Very late thrombosis after drug-eluting stents. Catheter. Cardiovasc. Interv. 68(1), 83–88 (2006).
   PubMed Web of Science ®Google Scholar
• Ozaki Y, Okumura M, Ismail TF et al. The fate of incomplete stent apposition with drug-eluting stents: an optical coherence tomography-based natural history study. Eur. Heart J. 31(12), 1470–1476 (2010).
   PubMed Web of Science ®Google Scholar
• Uren NG, Schwarzacher SP, Metz JA et al. Predictors and outcomes of stent thrombosis: an intravascular ultrasound registry. Eur. Heart J. 23(2), 124–132 (2002).
   PubMed Web of Science ®Google Scholar
• Fujii K, Carlier SG, Mintz GS et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J. Am. Coll. Cardiol. 45(7), 995–998 (2005).
   PubMed Web of Science ®Google Scholar
• McCann A, MacIsaac A, Whitbourn RJ. Late drug-eluting stent thrombosis: importance of intravascular ultrasound. Cardiovasc. Revasc. Med. 11(1), 52–56 (2010).
   PubMedGoogle Scholar
• Roy P, Steinberg DH, Sushinsky SJ et al. The potential clinical utility of intravascular ultrasound guidance in patients undergoing percutaneous coronary intervention with drug-eluting stents. Eur. Heart J. 29(15), 1851–1857 (2008).
   PubMed Web of Science ®Google Scholar
• Rogacka R, Latib A, Colombo A. IVUS-guided stent implantation to improve outcome: a promise waiting to be fulfilled. Curr. Cardiol. Rev. 5(2), 78–86 (2009).
   PubMedGoogle Scholar
• Bhatt DL, Fox KA, Hacke W et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354(16), 1706–1717 (2006).
   PubMed Web of Science ®Google Scholar
• Tsai TT, Ho PM, Xu S et al. Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: insights from the HMO Research Network-stent registry (HMORN-stent). Circ. Cardiovasc. Interv. 3(3), 230–235 (2010).
   PubMed Web of Science ®Google Scholar
• Kaiser C, Galatius S, Erne P et al. Drug-eluting versus bare-metal stents in large coronary arteries. N. Engl. J. Med. 363(24), 2310–2319 (2010).
   PubMed Web of Science ®Google Scholar
• Patti G, Barczi G, Orlic D et al. Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) randomized study. J. Am. Coll. Cardiol. 58(15), 1592–1599 (2011).
   PubMed Web of Science ®Google Scholar
• Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 111(16), 2099–2106 (2005).
   PubMed Web of Science ®Google Scholar
• Montalescot G, White HD, Gallo R et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N. Engl. J. Med. 355(10), 1006–1017 (2006).
   PubMed Web of Science ®Google Scholar
• Kim YH, Lee JY, Ahn JM et al. Impact of bleeding on subsequent early and late mortality after drug-eluting stent implantation. JACC Cardiovasc. Interv. 4(4), 423–431 (2011).
   PubMed Web of Science ®Google Scholar
• Musumeci G, Rossini R, Lettieri C et al. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. Catheter. Cardiovasc. Interv. 80(3), 395–405 (2012).
   PubMed Web of Science ®Google Scholar
• Rao AK, Pratt C, Berke A et al. Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J. Am. Coll. Cardiol. 11(1), 1–11 (1988).
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kumar S, Fusaro M et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 125(23), 2873–2891 (2012).
   PubMed Web of Science ®Google Scholar
• Palmerini T, Biondi-Zoccai G, Della Riva D et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 379(9824), 1393–1402 (2012).
   PubMed Web of Science ®Google Scholar
• Tamai H, Igaki K, Kyo E et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 102(4), 399–404 (2000).
   PubMed Web of Science ®Google Scholar
• Nishio S, Kosuga K, Igaki K et al. Long-term (>10 years) clinical outcomes of First-In-Man biodegradable Poly-l-lactic Acid coronary stents: igaki-tamai stents. Circulation (2012).
   Google Scholar
• Onuma Y, Serruys PW, Ormiston JA et al. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention 6(4), 447–453 (2010).
   PubMed Web of Science ®Google Scholar
• Ormiston JA, Serruys PW, Onuma Y et al. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circ. Cardiovasc. Interv. 5(5), 620–632 (2012).
   PubMed Web of Science ®Google Scholar
• Heublein B, Rohde R, Kaese V, Niemeyer M, Hartung W, Haverich A. Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology? Heart 89(6), 651–656 (2003).
   PubMed Web of Science ®Google Scholar
• Sternberg K, Gratz M, Koeck K et al. Magnesium used in bioabsorbable stents controls smooth muscle cell proliferation and stimulates endothelial cells in vitro. J. Biomed. Mater. Res. B. Appl. Biomater. 100(1), 41–50 (2012).
   PubMedGoogle Scholar
• Waksman R, Pakala R, Kuchulakanti PK et al. Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. Catheter. Cardiovasc. Interv. 68(4), 607–617 (2006).
   PubMed Web of Science ®Google Scholar
• Erbel R, Di Mario C, Bartunek J et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 369(9576), 1869–1875 (2007).
   PubMed Web of Science ®Google Scholar
• Waksman R, Erbel R, Di Mario C et al. Early- and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. JACC Cardiovasc. Interv. 2(4), 312–320 (2009).
   PubMed Web of Science ®Google Scholar
• Bourantas CV, Zhang Y, Farooq V, Garcia-Garcia HM, Onuma Y, Serruys PW. Bioresorbable scaffolds: current evidence and ongoing clinical trials. Curr. Cardiol. Rep. 14(5), 626–634 (2012).
   PubMed Web of Science ®Google Scholar
• Cremers B, Speck U, Kaufels N et al. Drug-eluting balloon: very short-term exposure and overlapping. Thromb. Haemost. 101(1), 201–206 (2009).
   PubMed Web of Science ®Google Scholar
• Kleber FX, Mathey DG, Rittger H, Scheller B. How to use the drug-eluting balloon: recommendations by the German consensus group. EuroIntervention 7( Suppl. K), K125–128 (2011).
   PubMed Web of Science ®Google Scholar
• Wohrle J, Zadura M, Mobius-Winkler S et al. SeQuentPlease World Wide Registry: clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study. J. Am. Coll. Cardiol. 60(18), 1733–1738 (2012).
   PubMed Web of Science ®Google Scholar
• Unverdorben M, Vallbracht C, Cremers B et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 119(23), 2986–2994 (2009).
   PubMed Web of Science ®Google Scholar
• Rittger H, Brachmann J, Sinha AM et al. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. J. Am. Coll. Cardiol. 59(15), 1377–1382 (2012).
   PubMed Web of Science ®Google Scholar
• Maier LS, Maack C, Ritter O, Bohm M. Hotline update of clinical trials and registries presented at the German Cardiac Society meeting 2008. (PEPCAD, LokalTax, INH, German ablation registry, German device registry, DES.DE registry, DHR, Reality, SWEETHEART registry, ADMA, GERSHWIN). Clin. Res. Cardiol. 97(6), 356–363 (2008).
   PubMed Web of Science ®Google Scholar
• Poss J, Jacobshagen C, Ukena C, Bohm M. Hotlines and clinical trial updates presented at the German Cardiac Society Meeting 2010: FAIR-HF, CIPAMI, LIPSIA-NSTEMI, Handheld-BNP, PEPCAD III, remote ischaemic conditioning, CERTIFY, PreSCD-II, German Myocardial Infarction Registry, DiaRegis. Clin. Res. Cardiol. 99(7), 411–417 (2010).
   PubMed Web of Science ®Google Scholar
• Belkacemi A, Agostoni P, Nathoe HM et al. First results of the DEB-AMI (drug eluting balloon in acute ST-segment elevation myocardial infarction) trial: a multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in primary percutaneous coronary intervention with 6-month angiographic, intravascular, functional, and clinical outcomes. J. Am. Coll. Cardiol. 59(25), 2327–2337 (2012).
   PubMed Web of Science ®Google Scholar
• Mohr FW, Morice MC, Kappetein AP et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 381(9867), 629–638 (2013).
   PubMed Web of Science ®Google Scholar
• Trenk D, Zolk O, Fromm MF, Neumann FJ, Hochholzer W. Personalizing antiplatelet therapy with clopidogrel. Clin. Pharmacol. Ther. 92(4), 476–485 (2012).
   PubMed Web of Science ®Google Scholar
• Ako J, Bonneau HN, Honda Y, Fitzgerald PJ. Design criteria for the ideal drug-eluting stent. Am. J. Cardiol. 100(8B), 3M–9M (2007).
   Web of Science ®Google Scholar